153Sm-EDTMP和骨膦治疗骨转移癌性疼痛

目的评价153Sm-EDTMP和 /或骨膦治疗骨转移癌症疼痛 60例的治疗效果.方法对 60例确诊为骨转移癌的患者随机分为3组,分别为 153Sm-EDTMP治疗组、骨膦治疗组和 153Sm-EDTMP加骨膦治疗组,观察止痛效果、骨病变有效率和毒副反应.结果153Sm-EDTMP组 30例、骨膦组 20例、联合用药组 10例的止痛有效率分别为80%, 85%和 90%; 3组分别比较差异无显著性意义(χ 2=1.597, P >0.05).3组骨病变有效率分别为20%, 10%和 50%;联合用药组与其他两组比较差异有显著性意义(χ 2=12.000,8.940, P< 0.05), 3组毒副反应均少.结论 153Sm-EDTMP加骨膦联合治疗是骨转移癌疼痛的优选疗法,疗效安全可靠.

Effects of 153Sm-EDTMPand bonefos on metastatic bone cancer pain

AIM:To evaluate the effect of 153Sm-EDTMP or/and bonefos in the treatment of metastatic bone cancer. METHODS:All 60 patients with metastatic bone cancer were divided into three groups:153Sm-EDTMP group, bonefos group and 153Sm-EDTMP plus bonefos group.The total remission rates of the bone pain, effective rates of the bone lesion and the side effect were observed comparatively. RESULTS:The remission rates of bone pain were 80% , 85% and 90% in 153Sm-EDTMP group, bonefos group and 153Sm-EDTMP plus bonefos group respectively. There were not significantly different among the three groups(P >0.05).The effective rates of bone lesion were 20% , 10% and 50% in above three groups respectively. The effect of 153Sm-EDTMP plus bonefos group was significantly better than that of 153Sm-EDTMP or bonefos group (P< 0.05). The side affects of three groups were rare. CONCLUSION:153Sm-EDTMP plus bonefos is an effective and safe therapy progress for patients with bone pain caused by metastic bone carcinoma.